Biotinylated polyclonal antibodies offer a tremendous binding affinity of avidin for biotin which can be assimilated through a varied range of conditions. As well as biotinylated polyclonal antibodies are utilized in various analytical techniques, including sandwich enzyme-linked immunosorbent assay, direct enzyme-linked immunosorbent assay, microarray, and immunohistochemistry. Biotinylated polyclonal antibodies are produced from specific and highly pure antigen affinity-purified polyclonal antibodies, and due to this it is ideally used for in any analytical procedures that require biotinylated antibodies.
This report contains market size and forecasts of Biotinylated Polyclonal Antibody in global, including the following market information:
Global Biotinylated Polyclonal Antibody Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Biotinylated Polyclonal Antibody Market Sales, 2017-2022, 2023-2028, (ml)
Global top five Biotinylated Polyclonal Antibody companies in 2021 (%)
The global Biotinylated Polyclonal Antibody market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Primary Antibody Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Biotinylated Polyclonal Antibody include Merck & Co., Inc, Abcam PLC, PerkinElmer, Inc, Thermo Fisher Scientific, Bio-Rad Laboratories, Lonza Group, Cell Signalling Technology, Inc, Agilent Technologies and F.Hoffmann La Roche Ltd. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Biotinylated Polyclonal Antibody manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Biotinylated Polyclonal Antibody Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (ml)
Global Biotinylated Polyclonal Antibody Market Segment Percentages, by Type, 2021 (%)
Primary Antibody
Secondary Antibody
Global Biotinylated Polyclonal Antibody Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (ml)
Global Biotinylated Polyclonal Antibody Market Segment Percentages, by Application, 2021 (%)
Immunocytochemistry (ICC)
Immunoprecipitation (IP)
Western Blot (WB)
In Situ Hybridization (ISH)
Immunohistochemistry (IHC)
Immunofluorescence (IF)
Global Biotinylated Polyclonal Antibody Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (ml)
Global Biotinylated Polyclonal Antibody Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Biotinylated Polyclonal Antibody revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Biotinylated Polyclonal Antibody revenues share in global market, 2021 (%)
Key companies Biotinylated Polyclonal Antibody sales in global market, 2017-2022 (Estimated), (ml)
Key companies Biotinylated Polyclonal Antibody sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck & Co., Inc
Abcam PLC
PerkinElmer, Inc
Thermo Fisher Scientific
Bio-Rad Laboratories
Lonza Group
Cell Signalling Technology, Inc
Agilent Technologies
F.Hoffmann La Roche Ltd